Research programme: MRP inhibitors - Xenova

Drug Profile

Research programme: MRP inhibitors - Xenova

Alternative Names: MRP inhibitors research programme - Xenova; XR-12890

Latest Information Update: 29 Jul 2004

Price : $50

At a glance

  • Originator Xenova Group
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Cancer

Most Recent Events

  • 29 Jul 2004 Discontinued - Preclinical for Asthma in United Kingdom (unspecified route)
  • 29 Jul 2004 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
  • 23 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top